3 August 2015.
Allan Tillack has accepted the position of Chair of the Generic and Biosimilar Medicines Association (GBMA), effective today.
Mr. Tillack has been the Sandoz Country Head for Australia and New Zealand since December 2013 and has a long history in the Australian pharmaceutical industry with prior commercial roles at Abbot Nutrition, Alphapharm, Monsanto and Astra. He previously held the position of GMiA Deputy Chair from July 2013 and together with the then Chair, Mr. Mark Crotty, secured a strategic agreement with the government to support the sustainability of the generic and biosimilar medicines industry in Australia, and deliver a 5-year period of certainty.
“The sustainability of our sector and the ongoing supply of affordable medicines is of paramount importance in the provision of quality health care to Australians. It’s an exciting time for the generics and biosimilars industry. We are ideally positioned to work with key stakeholders to deliver on tangible measures that directly address both access to and the affordability of high quality medicines to the patients that need them. Achieving this ambition will require developing a framework that supports and secures the viability of our industry.” Mr. Tillack said.
“Under the National Medicines Policy and through our Strategic Agreement, I will continue to engage with government proactively to ensure a future where fair pricing of affordable medicines meets the needs of patients, government and industry,”
“The GBMA today is a strong, focused organisation and I will build upon the important work done by my predecessor, Mark Crotty. We will deliver tangible benefits from the Strategic Agreement to deliver a sustainable generic and biosimilar medicines sector,” he said.
Stephen Fraser has accepted the role of Deputy Chair. He is the Managing Director ANZ at Alphapharm-Mylan and has been on the Board of GBMA since July 2013. Working closely with the Chair, Mr. Fraser will ensure the outcomes of the Strategic Agreement will result in the ongoing supply of affordable medicines and the viability of the industry that supplies them.
ENDS
